PL360990A1 - Vaccines containing ribavirin and methods of use thereof - Google Patents

Vaccines containing ribavirin and methods of use thereof

Info

Publication number
PL360990A1
PL360990A1 PL01360990A PL36099001A PL360990A1 PL 360990 A1 PL360990 A1 PL 360990A1 PL 01360990 A PL01360990 A PL 01360990A PL 36099001 A PL36099001 A PL 36099001A PL 360990 A1 PL360990 A1 PL 360990A1
Authority
PL
Poland
Prior art keywords
methods
vaccines containing
ribavirin
antigen
containing ribavirin
Prior art date
Application number
PL01360990A
Other languages
English (en)
Polish (pl)
Inventor
Matti Sallberg
Catharina Hultgren
Original Assignee
Tripep Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tripep Ab filed Critical Tripep Ab
Publication of PL360990A1 publication Critical patent/PL360990A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL01360990A 2000-08-17 2001-08-15 Vaccines containing ribavirin and methods of use thereof PL360990A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22576700P 2000-08-17 2000-08-17
US22917500P 2000-08-29 2000-08-29
US70554700A 2000-11-03 2000-11-03

Publications (1)

Publication Number Publication Date
PL360990A1 true PL360990A1 (en) 2004-09-20

Family

ID=27397520

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01360990A PL360990A1 (en) 2000-08-17 2001-08-15 Vaccines containing ribavirin and methods of use thereof

Country Status (12)

Country Link
US (1) US6960569B2 (enExample)
EP (3) EP1947185B1 (enExample)
JP (1) JP5175417B2 (enExample)
KR (2) KR20070114209A (enExample)
CN (1) CN100400101C (enExample)
AT (2) ATE375804T1 (enExample)
AU (4) AU2001290178A1 (enExample)
CA (1) CA2419418A1 (enExample)
DE (1) DE60130998T2 (enExample)
ES (1) ES2296803T3 (enExample)
PL (1) PL360990A1 (enExample)
WO (2) WO2002014362A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001290178A1 (en) 2000-08-17 2002-02-25 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
RU2286172C2 (ru) 2000-08-17 2006-10-27 Трипеп Аб Вакцины, содержащие рибавирин, и способы их использования
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6680059B2 (en) * 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
WO2002102307A2 (en) * 2001-06-15 2002-12-27 Ribapharm Nucleoside vaccine adjuvants
CA2497047A1 (en) * 2002-08-27 2004-03-11 Compound Therapeutics, Inc. Adzymes and uses thereof
CA2506525A1 (en) * 2002-11-26 2004-06-10 Tripep Ab Hepatisis c virus nonstructural protein 4a (ns4a) is an enhancer element
US7419912B2 (en) 2004-04-01 2008-09-02 Cree, Inc. Laser patterning of light emitting devices
EP1591539B1 (en) * 2004-04-29 2007-10-03 F. Hoffmann-La Roche Ag NS5A nucleoside sequence variation as a marker
AU2012200012B8 (en) * 2004-09-29 2014-05-01 The Administrators Of The Tulane Educational Fund Inhibitors of hepatitis C virus
WO2006039326A2 (en) * 2004-09-29 2006-04-13 The Administrators Of The Tulane Educational Fund Inhibitors of hepatitits c virus
WO2008004992A2 (en) * 2005-05-25 2008-01-10 Tripep Ab Transdermal formulations containing hepatitis c virus immunogens and an ethoxylated oil
EP1888751A2 (en) * 2005-05-25 2008-02-20 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
ES2334472B1 (es) * 2006-06-09 2011-01-21 Proyecto De Biomedicina Cima, S.L. Combinacion inmunoestimuladora para profilaxis y tratamiento de hepatitis c.
DE602006014720D1 (de) * 2005-10-07 2010-07-15 Proyecto Biomedicina Cima Sl Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
CN101663399B (zh) * 2007-12-18 2013-01-02 北京大学人民医院 一种抗hcv的疫苗及其制备方法和用途
WO2009130588A2 (en) * 2008-04-22 2009-10-29 Tripep Ab Immunogen platform
CN108148121B (zh) * 2018-03-06 2021-07-09 中美赛尔生物科技(广东)有限公司 丙型肝炎病毒抗原多肽组合物以及丙型肝炎病毒疫苗

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2933693A (en) 1957-05-03 1960-04-19 Lyle R Battersby Sensitivity control circuit
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4818540A (en) 1985-02-25 1989-04-04 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US5643565A (en) * 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5714596A (en) * 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
US5698390A (en) * 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
US5679342A (en) * 1987-11-18 1997-10-21 Chiron Corporation Hepatitis C virus infected cell systems
US5968775A (en) * 1987-11-18 1999-10-19 Chiron Corporation Hepatitis C virus infected cell systems
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
IE62868B1 (en) * 1987-11-18 1995-03-08 Chiron Corp Hepatitis C virus
US5712088A (en) * 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US6171782B1 (en) * 1987-11-18 2001-01-09 Chiron Corporation Antibody compositions to HCV and uses thereof
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US4950647A (en) * 1988-10-04 1990-08-21 Nucleic Acid Research Institute T cell immunopotentiator
KR0185373B1 (ko) 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6027729A (en) * 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
EP0398748B1 (en) 1989-05-18 2002-01-09 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
DE69031791T2 (de) 1989-08-25 1998-04-02 Chiron Corp Verfahren zur HCV-Züchtung in Zell-Linien aus B- oder T-Lymphozyten
JP3156200B2 (ja) * 1989-09-15 2001-04-16 国立予防衛生研究所長 新規のｈｃｖ分離株
US5372928A (en) * 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
US6194140B1 (en) 1990-04-04 2001-02-27 Chiron Corporation HCV NS3 protein fragments having helicase activity and improved solubility
US6312889B1 (en) * 1990-04-04 2001-11-06 Chiron Corporation Combinations of hepatitis c virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
PL169273B1 (pl) * 1990-04-04 1996-06-28 Chiron Corp skierowanej przeciw wirusowi zapalenia watroby C PL
WO1991015771A1 (en) 1990-04-04 1991-10-17 Chiron Corporation Combinations of hepatitis c virus (hcv) antigens for use in immunoassays for anti-hcv antibodies
EP0543924B1 (en) 1990-08-10 1997-06-18 Chiron Corporation Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus
CA2027434C (en) 1990-10-12 1999-01-05 George Jackowski Diagnostic kit for diagnosing and distinguishing chest pain in early onset thereof
US5710008B1 (en) 1990-10-12 1999-09-07 Spectral Diagnostics Inc Method and device for diagnosing and distinguishing chest pain in early onset thereof
US5604105B1 (en) 1990-10-12 1999-08-24 Spectral Diagnostics Inc Method and device for diagnosingand distinguishing chest pain in early onset thereof
SK285623B6 (sk) 1990-11-08 2007-05-03 Chiron Corporation Spôsob produkcie asialoglykoproteínu hepatitis C vírusu
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
DE69132531T2 (de) 1990-12-06 2001-09-13 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verbindungen und ihre Verwendung in einer binären Synthesestrategie
US6190864B1 (en) * 1991-05-08 2001-02-20 Chiron Corporation HCV genomic sequences for diagnostics and therapeutics
CZ288720B6 (cs) 1991-05-08 2001-08-15 Chiron Corporation Nukleová kyselina, kompozice s jejím obsahem, způsob tvorby hybridizačního produktu a způsob detekce genotypů HCV
FR2677372B1 (fr) * 1991-06-06 1994-11-10 Pasteur Institut Sequences nucleotidiques et peptidiques d'un isolat de virus de l'hepatite c, applications diagnostiques et therapeutiques.
ES2188583T3 (es) * 1991-06-24 2003-07-01 Chiron Corp Polipeptidos para el virus de la hepatitis c (hcv).
WO1993006126A1 (en) * 1991-09-13 1993-04-01 Chiron Corporation Immunoreactive hepatitis c virus polypeptide compositions
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5795714A (en) 1992-11-06 1998-08-18 Trustees Of Boston University Method for replicating an array of nucleic acid probes
DE4239311C2 (de) 1992-11-23 1996-04-18 Guehring Joerg Dr Bohrer, insbesondere Spitzbohrwerkzeug mit austauschbarem Schneideinsatz
PT681483E (pt) 1993-01-26 2005-11-30 Wyeth Corp Composicoes e metodos para distribuicao de material genetico
ATE551423T1 (de) * 1993-04-27 2012-04-15 Innogenetics Nv Sequenzen von hepatitis c virus-genotypen sowie ihre verwendungen als therapeutika und diagnostika
AU8126694A (en) 1993-10-26 1995-05-22 Affymax Technologies N.V. Arrays of nucleic acid probes on biological chips
ES2182914T3 (es) 1994-09-23 2003-03-16 Zonagen Inc Inmunopotenciacion inducida de quitosan.
US6235888B1 (en) 1994-10-05 2001-05-22 The General Hospital Corporation Hepatitis C virus vaccine
WO1996013590A2 (en) * 1994-10-21 1996-05-09 Innogenetics N.V. New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
FR2730935A1 (fr) * 1994-12-21 1996-08-30 Vacsyn Sa Vaccin presentant une immunogenicite accrue
US5932556A (en) * 1995-09-17 1999-08-03 Tam; Robert C Methods and compositions for regulation of CD28 expression
WO1996028162A1 (en) 1995-03-14 1996-09-19 University Of Medicine & Dentistry Of New Jersey New drug combination for the treatment of viral diseases
US5767097A (en) * 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US6150337A (en) * 1996-01-23 2000-11-21 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
IL125088A0 (en) * 1996-01-23 1999-01-26 Icn Pharmaceuticals Modulation of TH1/TH2 cytokine expression
AU2189397A (en) 1996-02-08 1997-08-28 Affymetrix, Inc. Chip-based speciation and phenotypic characterization of microorganisms
EP2368897B1 (en) 1996-02-09 2016-10-19 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US6514731B1 (en) * 1996-05-24 2003-02-04 Chiron Corporation Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens
JP2002500502A (ja) * 1996-06-11 2002-01-08 メルク エンド カンパニー インコーポレーテッド 合成ｃ型肝炎遺伝子
CA2266656A1 (en) * 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
JP2002503212A (ja) 1996-10-16 2002-01-29 アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド 単環式ヌクレオシド、その類似体および使用
CA2266889A1 (en) 1996-10-16 1998-04-23 Guangyi Wang Purine l-nucleosides, analogs and uses thereof
IL119833A (en) 1996-12-15 2001-01-11 Lavie David Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
EP0998293A4 (en) 1997-01-17 2002-07-17 Icn Pharmaceuticals TREATMENTS FOR CYTOKIN-RELATED DISEASES
JP2001512308A (ja) 1997-02-07 2001-08-21 メルク エンド カンパニー インコーポレーテッド 合成ｈｉｖ ｇａｇ遺伝子
WO1998037180A2 (en) 1997-02-22 1998-08-27 Abbott Laboratories Hcv fusion protease and polynucleotide encoding same
US6153421A (en) * 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof
WO1999028482A2 (en) * 1997-11-28 1999-06-10 Schering Corporation Single-chain recombinant complexes of hepatitis c virus ns3 protease and ns4a cofactor peptide
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
DE69939132D1 (de) * 1998-04-17 2008-08-28 Innogenetics Nv Verfahren zur Verbesserung der Proteinkonformation mit Hilfe von Reduktionsmitteln
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
AU2483300A (en) 1999-01-29 2000-08-18 Icn Pharmaceuticals, Inc. Modulation of immune response by ribavirin
US20020187945A1 (en) * 1999-01-29 2002-12-12 Robert Tam Modulation of immune response by ribavirin
EP1233982B1 (en) * 1999-11-24 2007-10-24 Novartis Vaccines and Diagnostics, Inc. Novel hcv non-structural polypeptide
ATE368221T1 (de) 2000-06-15 2007-08-15 Novartis Vaccines & Diagnostic Immunoassays für anti-hcv-antikörper
AU2001290178A1 (en) * 2000-08-17 2002-02-25 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
JP4475561B2 (ja) 2001-10-11 2010-06-09 メルク・シャープ・エンド・ドーム・コーポレイション Ｃ型肝炎ウイルスワクチン
KR20140137679A (ko) 2013-05-23 2014-12-03 삼성전자주식회사 카드 소켓 장치

Also Published As

Publication number Publication date
AU2001292151C1 (en) 2002-02-25
AU2001290178A1 (en) 2002-02-25
DE60130998T2 (de) 2008-07-17
CA2419418A1 (en) 2002-02-21
EP2332574A1 (en) 2011-06-15
AU9215101A (en) 2002-02-25
EP1311289B1 (en) 2007-10-17
ATE517184T1 (de) 2011-08-15
KR100801123B1 (ko) 2008-02-05
AU2001292151B2 (en) 2006-05-04
JP2004506018A (ja) 2004-02-26
KR20070114209A (ko) 2007-11-29
KR20030024876A (ko) 2003-03-26
AU2006203358B2 (en) 2008-07-17
WO2002013855A3 (en) 2003-01-09
EP1947185B1 (en) 2011-07-20
AU2006203358A1 (en) 2006-08-31
EP1311289A2 (en) 2003-05-21
CN1469755A (zh) 2004-01-21
DE60130998D1 (de) 2007-11-29
JP5175417B2 (ja) 2013-04-03
US20040092730A1 (en) 2004-05-13
EP1947185A1 (en) 2008-07-23
ES2296803T3 (es) 2008-05-01
WO2002014362A3 (en) 2003-11-13
WO2002014362A2 (en) 2002-02-21
US6960569B2 (en) 2005-11-01
WO2002013855A2 (en) 2002-02-21
ATE375804T1 (de) 2007-11-15
CN100400101C (zh) 2008-07-09

Similar Documents

Publication Publication Date Title
AU9215101A (en) Vaccines containing ribavirin and methods of use thereof
DK1090033T4 (da) Partikler af HCV-kappeproteiner: Anvendelse til vaccination
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
IL211037A (en) Antigen @ reactant @ with @ serum @ hyper
SG156652A1 (en) Yeast-based therapeutic for chronic hepatitis c infection
EP1200109A4 (en) USE OF PEPTIDE NUCLEIC ACID COMPOUNDS TO TRIGGER CELLULAR IMMUNE RESPONSES TO HEPATITIS C
IL153474A0 (en) Human papilloma virus treatment
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
ATE485056T1 (de) Verbesserte impfstoffe
ATE402715T1 (de) Hcv-impfstoff zusammensetzungen
MXPA02011545A (es) Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.
BR0108499A (pt) Agente terapêutico para hepatite c
MXPA03006971A (es) Tratamiento del virus de hepatitis b.
WO2002060954A8 (en) Materials and methods for treatment of hepatitis c
WO2004043404A3 (en) Process for designing inhibitors of influenza virus non-structural protein 1
MXPA03009763A (es) Vacuna contra el virus de la enfermedad de la fiebre aftosa.
WO2002015664A3 (en) Methods of preventing or treating west nile virus and other infections
DE602006014720D1 (de) Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
DK1074266T3 (da) Levende svækkede bakterier til anvendelse i vaccine
BR0101523A (pt) Pestivìrus, vacina, e, processos para imunizarcontra doença induzida por pestivìrus e parafabricar uma vacina para a proteção de um animalcontra um pestivìrus
RU2004104357A (ru) Вакцинный состав, потенцированный комбинацией днк и антигена
WO2004064784A3 (en) Composition and method for preventing or treating a virus infection
AU2003299493A8 (en) Compositions and methods for the treatment of hepatitis c virus infection

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)